| SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | |
| | |
MedLine Citation:
|
PMID: 22310849 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
This Review covers the rationale, physiological consequences and clinical application of pharmacological sodium-glucose cotransporter 2 (SGLT2) inhibition. In patients with type 2 diabetes mellitus, in whom renal glucose reabsorption might be upregulated, orally active, selective SGLT2 inhibitors improve glycaemic control to a therapeutically useful extent. Chronic administration of several SGLT2 inhibitors dose-dependently lowers HbA(1c) levels by 0.5-1.5% without causing hypoglycaemia. The unique mechanism of action of SGLT2 inhibitors-which does not hinge upon β-cell function or tissue insulin sensitivity-means that they can exert their antihyperglycaemic effects in combination with any other oral antidiabetic drug as well as insulin. Available phase III studies confirm a good tolerability profile. Weight loss owing to urinary calorie leakage may be less than expected, but the negative energy balance offers a valuable clinical benefit. Offloading of sodium can assist blood pressure control. The progressive loss of efficacy in patients with reduced glomerular function will have to be balanced against the possibility of renal protection. The safety issues of genitourinary infections and cancer risk requires careful, proactive monitoring and analysis of robust exposure data, particularly in elderly, frail patients and in patients with impaired kidney function and/or high cardiovascular/cancer risk, who represent an increasing fraction of the population with diabetes mellitus. |
| | |
Authors:
|
Ele Ferrannini; Anna Solini |
Related Documents
:
|
10651749 - The effects of growth hormone replacement therapy on overnight metabolic fuels in hypop... 7881809 - Endocrine and metabolic responses of intact and hypophysectomized turkey poults given a... 21321409 - Homocysteine levels and the metabolic syndrome in a mediterranean population: a case-co... 9186309 - Growth hormone (gh) response to gh-releasing peptide-6 in patients with insulin-depende... 10435659 - Enteral insulin-like growth factor-i augments intestinal disaccharidase activity in pig... 12735929 - Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in a... 20225769 - Reliability of the neurological scores for assessment of sensorimotor neuropathy in typ... 1357529 - Insulin response of cultured islets from diabetic and nondiabetic bb rats. 18216319 - A pai-1 mutant, pai-1r, slows progression of diabetic nephropathy. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-07 |
Journal Detail:
|
Title: Nature reviews. Endocrinology Volume: - ISSN: 1759-5037 ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-7 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101500078 Medline TA: Nat Rev Endocrinol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Internal Medicine, University of Pisa School of Medicine, Via Roma 67, 56100 Pisa, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oxidative Stress Responses and Recovery Patterns in the Liver of Oreochromis niloticus Exposed to Ch...
Next Document: Intensive insulin therapy in the ICU-reconciling the evidence.